Paragon Biosciences, a leading global life science company, has a steadfast commitment to accelerating biology-based breakthroughs to treat and cure diseases. The company’s patient-centric approach, coupled with its dedication to research and development, underscores its focus on transforming the lives of people with unmet medical needs.
Founded by Jeff Aronin, Paragon Biosciences has made numerous contributions across various domains of life science innovation.
The integration of AI into the life science landscape is a game changer. Paragon’s proprietary AI technology enables the analysis of vast and intricate protein datasets, offering the possibility to develop personalized treatments and breakthrough therapies. By harnessing the power of AI, Paragon Biosciences has technology that speeds up the drug development process and may lead to the identification of novel therapeutic targets.
Paragon’s work in cell and gene therapy is ushering in a new era of medical possibilities. Through innovative cell and gene therapies, the company is developing novel treatments to target genetic disorders at their root cause. These groundbreaking therapeutics offer hope to patients with previously untreatable conditions, providing a chance at a better quality of life.
Biopharmaceuticals are an important area of focus for Paragon. Currently, Paragon’s portfolio company, Emalex Biosciences, is investigating a potential therapeutic to reduce tics in children and adolescents with Tourette Syndrome. Tourette’s is a neurological disorder characterized by involuntary physical and verbal tics.
Paragon Biosciences continues to push the boundaries of biology-based innovation to help treat and cure diseases.